Latest Breaking News On - Astellas inc - Page 1 : vimarsana.com

European Commission Approves Pfizer s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer -January 08, 2024 at 10:36 am EST

European Commission Approves Pfizer s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer -January 08, 2024 at 10:36 am EST
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesRobert jonesLab abnormalitiesMedivation incWorld health organization global cancer observatoryEuropean commissionEuropean unionExchange commissionUniversity of glasgowAstellas incProfessor of clinical cancer researchPfizer incClinical cancer researchErik briersVice chairmanHazard ratio

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesNaoki okamuraAhsan arozullahDrug administrationMedivation incAmerican society of clinical oncologyEuropean unionAmerican urological association annual meeting onAstellas incHead of oncology developmentEuropean medicines agencyAstellas pharma incPrnewswire astellas pharma incSenior vice presidentOncology developmentUrological association annual meeting

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

United statesAhsan arozullahNaoki okamuraDrug administrationMedivation incAstellas pharma incEuropean unionAmerican society of clinical oncologyHead of oncology developmentAstellas incAmerican urological association annual meeting onEuropean medicines agencyEuropean medicines agency validates typeNon metastatic hormone sensitive prostate cancerHigh risk biochemicalSenior vice president

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Medicines Agency (EMA) has.

United statesAhsan arozullahNaoki okamuraMedivation incDrug administrationEuropean unionPrnewswire astellas pharma incAmerican urological association annual meeting onAmerican society of clinical oncologyHead of oncology developmentEuropean medicines agencyAstellas pharma incAstellas incSenior vice presidentOncology developmentUrological association annual meeting

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

/PRNewswire/ Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food.

United statesChris boshoffAhsan arozullahNaoki okamuraPrnewswire pfizer incAstellas incExchange commissionHead of oncology developmentAstellas pharma incEuropean unionAmerican society of clinical oncologyDrug administrationOncology researchLab abnormalitiesMedivation incAstellas pharma